Steven Cummings, MD: The denosumab FREEDOM trial

August 11, 2009- Dr. Steven Cummings, director of the San Francisco Coordinating Center and faculty of UCSF, and principle investigator of the Amgen FREEDOM trial, discusses the results of the trial. FREEDOM looked at 8,500 postmenopausal patients and followed them for three years. The outcome measures were fracture rates in different areas (vertebral, nonvertebral, hip). The study showed a strong efficacy for twice-yearly subcutaneous injected denosumab with minimal adverse events (infection being the main concern). There were no reports of ONJ as has been reported with high doses of bisphosonates.